PMID- 10510158
OWN - NLM
STAT- MEDLINE
DCOM- 19991116
LR  - 20240314
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 48
IP  - 3
DP  - 1999 Sep
TI  - Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and 
      theophylline.
PG  - 438-44
AB  - AIMS: Theophylline is a model substrate of cytochrome P4501A2. The ability of the 
      proton pump inhibitors (PPI) omeprazole, lansoprazole and pantoprazole to induce 
      cytochrome P4501A2 has not yet been unequivocally resolved. The aim of this 
      comprehensive study was to compare directly the effect of the three PPI on the 
      absorption and disposition of theophylline. METHODS: Twenty healthy, nonsmoking, 
      male and female volunteers (extensive metabolisers of cytochrome P4502C19 and 
      Helicobacter pylori negative) participated in a randomized, double-blind, 
      four-period, placebo-controlled crossover study. In each of the four periods they 
      received either omeprazole (40 mg), lansoprazole (60 mg), pantoprazole (80 mg) or 
      placebo once daily for 10 days. Sustained release theophylline (350 mg twice 
      daily) was coadministered from day 8-10. Pharmacokinetics of theophylline as well 
      as of all three PPI were determined at steady-state (day 10). RESULTS: In all 
      periods, point estimates and 90% confidence intervals of the area under the 
      concentration-time curves (AUC), maximum steady-state concentrations and 
      peak-trough fluctuations of theophylline were not altered by PPI pretreatment and 
      met the required limits for bioequivalence. Point estimates (90% confidence 
      intervals) of the AUC ratios of theophylline plus PPI to theophylline alone were 
      0.92 (0.87-0.97), 0.90 (0.85-0.95) and 1.00 (0.95-1.06) for omeprazole, 
      lansoprazole and pantoprazole, respectively. CONCLUSIONS: Concomitant intake of 
      omeprazole, lansoprazole or pantoprazole at high therapeutic doses does not 
      affect the absorption and disposition of theophylline.
FAU - Dilger, K
AU  - Dilger K
AD  - Dr Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Stuttgart, 
      Germany.
FAU - Zheng, Z
AU  - Zheng Z
FAU - Klotz, U
AU  - Klotz U
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - C137DTR5RG (Theophylline)
RN  - D8TST4O562 (Pantoprazole)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A2)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Area Under Curve
MH  - Benzimidazoles/*pharmacology
MH  - Bronchodilator Agents/pharmacokinetics
MH  - Cross-Over Studies
MH  - Cytochrome P-450 CYP1A2/metabolism
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Omeprazole/*analogs & derivatives/*pharmacology
MH  - Pantoprazole
MH  - Proton Pump Inhibitors
MH  - Sulfoxides/*pharmacology
MH  - Theophylline/*pharmacokinetics
PMC - PMC2014345
EDAT- 1999/10/06 00:00
MHDA- 1999/10/06 00:01
PMCR- 2000/03/01
CRDT- 1999/10/06 00:00
PHST- 1999/10/06 00:00 [pubmed]
PHST- 1999/10/06 00:01 [medline]
PHST- 1999/10/06 00:00 [entrez]
PHST- 2000/03/01 00:00 [pmc-release]
AID - bcp043 [pii]
AID - 10.1046/j.1365-2125.1999.00043.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1999 Sep;48(3):438-44. doi: 
      10.1046/j.1365-2125.1999.00043.x.